Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Citius Pharmaceuticals Inc
(NQ:
CTXR
)
0.6019
+0.0727 (+13.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Citius Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
February 13, 2023
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday.
Via
Benzinga
Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
February 13, 2023
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 18, 2023
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+...
Via
Benzinga
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm
May 25, 2022
Via
Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
May 07, 2022
Via
Get News
Exposures
Product Safety
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
January 18, 2023
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 26, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 23, 2022
Via
Benzinga
Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket
October 17, 2022
Gainers
Via
Benzinga
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
April 06, 2022
Via
Benzinga
11 Health Care Stocks Moving In Friday's Pre-Market Session
September 23, 2022
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.
Via
Benzinga
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
September 23, 2022
Via
Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
August 11, 2022
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 11, 2022
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
July 22, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 07, 2022
Gainers
Via
Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
May 11, 2022
Via
Get News
Exposures
Product Safety
3 Reddit Stocks to Buy in May
May 08, 2022
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond
Via
InvestorPlace
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
May 04, 2022
Via
AB Newswire
Exposures
Product Safety
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
May 04, 2022
Via
Viz Release
Exposures
COVID-19
Product Safety
First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
April 26, 2022
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 06, 2022
Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6...
Via
Benzinga
61 Biggest Movers From Yesterday
April 28, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 17, 2022
Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of...
Via
Benzinga
Penny Stock Watchlist - Here Are My Five Top Picks
February 17, 2022
If you got into Amazon at the start of 2021, by the end of 2021 you'd have made about 73% gains. Not bad for a year. It's impressive until you consider that one of these stocks made 258% gains in the...
Via
Talk Markets
FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids
February 15, 2022
The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido to treat hemorrhoids. The Company anticipates...
Via
Benzinga
Citius Pharmaceuticals: Q1 Earnings Insights
February 10, 2022
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius...
Via
Benzinga
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.